Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?

REFERENCES

• Barratt G. Colloidal drug carriers: Achievements and perspectives. Cell Mol Life Sci 2003; 60: 21–37
   PubMed Web of Science ®Google Scholar
• Breyer R, Hussein S, Radu DL, et al. Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. I Neurosurg 2000; 92: 140–149
   PubMed Web of Science ®Google Scholar
• Brioschi A, Guido M, CavaIli R, et al. Enhanced cytotoxicity of doxorubicin and paclitaxel incorporated in solid lipid nanoparti-cles against human glioma cells. Funct Neurol 2001; 16: 203
   Google Scholar
• Brioschi A, Calderoni S, Pradotto LG, Guido M, Strada A, Zenga F, Benech CA, Benech F, Serpe L, Zara GP, Musicanti C, Ducati A, Gasco MR, Mauro A. Solid lipid nanoparticles carrying oligonu-cleotides inhibit VEGF expression in rat glioma models. 2007, submitted
   Google Scholar
• Brioschi AM, Calderoni S, Guido M, et al. Butyrric acid cholesterol ester nanospheres for glioma therapy: In vitro and in vivo study in a rat cerebral glioma model. J Neurol 2004; 251 (Suppl. 3): III/11
   Google Scholar
• Calderoni S, Brioschi A, Guido M, et al. Solid I ipidic nanoparticles vehiculating doxorubicin and colloidal Fe2+ in C6 glioma cell cultures: Confocal and electron microscopy study. Clin Neuropathol 2002; 21: 110–111
   Google Scholar
• Calderoni S, Guido M, Re S, et al. A possible pro-drug in the cerebral glioma systemic treatment: Butyric acid cholesterol ester. Brain Pathol 2003; 13: S28—S29
   Google Scholar
• Carpentier AF. Neuro-oncology: The growing role of chemother-apy in glioma. Lancet Neurol 2005; 4: 4–5
   PubMed Web of Science ®Google Scholar
• Cavalli R, Caputo 0, Carlotti ME, et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Intl Pharm 1997; 148: 47–54
   Web of Science ®Google Scholar
• Cavalli R, Caputo 0, Gasco MR. Preparation and characterization of solid lipid nanospheres containing paclitaxel. Eur] Pharm Sci 2000; 10: 305–309
   PubMed Web of Science ®Google Scholar
• Chen DB, Yang TZ, Lu WL, et al. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bull (Tokyo) 2001; 49: 1444–1447
   PubMed Web of Science ®Google Scholar
• Conway RM, Madigan MC, Penfold PL, et al. Induction of apoptosis by sodium butyrate in the human Y-79 retinoblastoma cell line. Oncol Res 1995; 7: 289–297
   PubMed Web of Science ®Google Scholar
• Dass CR. Vehicles for oligonucleotide delivery to tumours. J Pharm Pharmacol 2002; 54: 3–27
   PubMed Web of Science ®Google Scholar
• De Angelis LM. Brain tumors. N Engl J Med 2001; 344: 114–123
   PubMed Web of Science ®Google Scholar
• Di Marco A, Zunino F, Casazza AM. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 1978; 23: 12–20
   PubMedGoogle Scholar
• Farhadi MR, Capelle HH, Erber R, et al. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: Effects on the angiogenesis, microcirculation, and growth of orthotropic malignant gliomas. I Neurosurg 2005; 102: 363–370
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Fundaria A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2002; 42: 337–343
   Web of Science ®Google Scholar
• Gasco MR. Solid lipid nanospheres from warm micro-emulsions. Pharm Technol Eur 1997; 9: 52–58
   Google Scholar
• Gasco MR. Liquid and solid colloidal therapeutic systems. Curr Top Coll Interf Sci 1997; 2:156–171
   Google Scholar
• Gasco MR. Solid lipid nanoparticles for drug delivery. Pharm Technol Eur 2001; 13: 32–42
   Google Scholar
• Göppert TM, Muller RH. Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Intl Pharm 2005; 302: 172–186
   PubMed Web of Science ®Google Scholar
• Göppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns. Drug Target 2005; 13: 179–187
   PubMed Web of Science ®Google Scholar
• Guido M, Brioschi A, Mighetta A, et al. Cytotoxic effects of doxorubicin and paclitaxel incorporated in solid lipid nanospar-ticles against malignant glioma cells. Neuro-Oncology 2001; 3 (Suppl. 1): S72
   Google Scholar
• Guido M, Brioschi A, Pradotto L, et al. Efficacy of systemic treatment with doxorubicin incorporated in solid lipidic nanopar-ticles in a rat C6 glioma brain tumor model. Clin Neuropathol 2002; 21: 121
   Google Scholar
• Ke LD, Shi YX, Im SA, et al. The relevance of cell proliferation, vascular endothelial growth factor, and basic fibroblast growth factor production to angiogenesis and tumorigenicity in human glioma cell lines. Clin Cancer Res 2000; 6: 2562–2572
   PubMed Web of Science ®Google Scholar
• Ke LD, Shi YX, Yung WK. VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells. Cancer Res 2002; 62:1854–1861
   PubMed Web of Science ®Google Scholar
• Kleihues P, Cavence WK, eds. World Health Organization Classification of Tumours. Pathology and Genetic Tumours of the Nervous System, Lyon: IARC Press, 2000
   Google Scholar
• Krum JM, Rosenstein JM. VEGF mRNA and its receptor fit-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. Exp Neurol 1998; 154: 57–65
   PubMed Web of Science ®Google Scholar
• Jansen M, de Witt Hamer PC, Witmer AN, et al. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res Brain Res Rew 2004; 45: 143–163
   PubMed Web of Science ®Google Scholar
• Johansson M, Brannstrom T, Bergenheim AT, et al. Spatial expression of VEGF-A in human glioma. I Neurooncol 2002; 59: 1–6
   PubMed Web of Science ®Google Scholar
• Jores K, Mehnert W, Drechsler M, et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. I Control Rel 2004; 95: 217–227
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. Biol Chem 1981; 256: 10435–10441
   Google Scholar
• Lamszus K, Brockmann MA, Eckerich C, et al. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 2005; 11: 4934–4940
   PubMed Web of Science ®Google Scholar
• Louis DN, Pomery SL, Cairncross JG. Focus on central nervous system neoplasia. Cancer Cell 2002; 1: 125–128
   PubMed Web of Science ®Google Scholar
• Luhrs H, Kudlich T, Neumann M, et al. Butyrate-enhanced TNFalpha-induced apoptosis is associated with inhibition of NF-kappaB. Anticancer Res 2002; 22: 1561–1568
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribu-tion and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration.] Control Rel 2005; 107: 215–228
   PubMed Web of Science ®Google Scholar
• Mauro A, Miglietta A, Cavalli R, et al. Enhanced cytotoxicity of paclitaxel incorporated in solid lipid nanoparticles against human glioma cells. Proc Int Symp Control Rel Bioact Mater 2000; 27: 377–378
   Google Scholar
• Mauro A, Guido M, Brioschi A, et al. Apoptosis and growth arrest induced in glioma cell lines by cholesteryl butyrate solid lipid nanospheres. Neuro-Oncology 2001; 3 (Suppl. 1): S75
   Google Scholar
• Mauro A, Brioschi A, Guido M, et al. Doxorubicin incorporated in solid lipid nanoparticles: In vivo study in an animal model of cerebral glioma. Present at the 7th European Congress of Neuropathology, 2002, Helsinki, Finland
   Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165–196
   PubMed Web of Science ®Google Scholar
• Menzel T, Schauber J, Kreth F, et al. Butyrate and aspirin in combination have an enhanced effect on apoptosis in human colorectal cancer cells. Eur] Cancer Prey 2002; 11: 271–281
   PubMed Web of Science ®Google Scholar
• Miglietta A, Cavalli R, Bocca C, et al. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000; 210: 61–67
   PubMed Web of Science ®Google Scholar
• Minow RA, Benjamin RS, Lee ET, et al. Adriamycin cardiomyo-pathy — risk factors. Cancer 1977; 39: 1397–1402
   PubMed Web of Science ®Google Scholar
• Mischel PS, Cloughesy TF. Targeted molecular therapy of GBM. Brain Pathol 2003; 13: 52–61
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. Eur] Pharm Biopharm 2000; 50: 161–177
   PubMed Web of Science ®Google Scholar
• Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs — a review of drug nanocrystal technology and lipid nanoparticles. I Biotechnol 2004; 113: 151–170
   Google Scholar
• Nudelman A, Gnizi E, Katz Y, et al. Prodrugs of butyric acid. Novel derivatives possessing increased aqueous solubility and potential for treating cancer and blood diseases. Eur] Med Chem 2001; 36: 63–74
   PubMed Web of Science ®Google Scholar
• Olbrich C, Bakowsky U, Lehr CM, et al. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. Control Rel 2001; 77: 345–355
   PubMed Web of Science ®Google Scholar
• Peira E, Marzola P, Podio V, et al. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 2003; 11: 19–24
   PubMed Web of Science ®Google Scholar
• Peoc'h M, Farion R, Hiou A, et al. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 2002; 22: 2147–2152
   PubMed Web of Science ®Google Scholar
• Podio V, Zara GP, Carazzone M, et al. Biodistribution of stealth and non-stealth solid lipid nanoparticles after intravenous admin-istration to rats. Pharm Pharmacol 2000; 52: 1057–1063
   PubMed Web of Science ®Google Scholar
• Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 2004; 3: 430–446
   PubMed Web of Science ®Google Scholar
• Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 2004; 187: 246–253
   PubMed Web of Science ®Google Scholar
• Salomone B, Ponti R, Gasco MR, et al. In vitro effects of cholesteryl butyrate solid lipid nanospheres as a butyric acid pro-drug on melanoma cells: Evaluation of antiproliferative activity and apoptosis induction. Clin Exp Metastasis 2000; 18: 663–673
   PubMed Web of Science ®Google Scholar
• Shenoy VS, Vijay IK, Murthy RS. Tumour targeting: Biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol 2005; 57: 411–421
   PubMed Web of Science ®Google Scholar
• Scholer N, Olbrich C, Tabatt K, et al. Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages. Int J Pharm 2001; 221: 57–67
   PubMed Web of Science ®Google Scholar
• Scholer N, Hahn H, Muller RH, et al. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002; 231: 167–176
   PubMed Web of Science ®Google Scholar
• Serpe L, Guido M, Canaparo R, et al. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J Nanosci Nanotechnol 2006; 6: 3062–3069
   PubMed Web of Science ®Google Scholar
• Stan AC, Casares S, Radu D, et al. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res 1999; 19:941–950
   PubMed Web of Science ®Google Scholar
• Tabatt K, Sameti M, Olbrich C, et al. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm 2004; 57: 155–162
   PubMed Web of Science ®Google Scholar
• Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667–673
   PubMed Web of Science ®Google Scholar
• Ugazio E, Marengo E, Pell izzaro C, et al. The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation. Eur J Pharm Biopharm 2001; 52: 197–202
   PubMed Web of Science ®Google Scholar
• von Hoist H, Knochenhauer E, Blomgren H, et al. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien) 1990; 104: 13–16
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser 0, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56: 1257–1272
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, et al. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. I Control Rel 1999; 59: 299-307
   PubMed Web of Science ®Google Scholar
• Yano A, Shingo T, Takeuchi A, et al. Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J Neurosurg 2005; 103: 104–114
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Shingo T, Muraoka K, et al. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res 2005; 1038: 1–10
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Fundaro A, et al. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res 1999; 40: 281–286
   PubMed Web of Science ®Google Scholar
• Zara GP, Cavalli R, Bargoni A, et al. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: Pharmacokinetics and distribution of doxorubicin in brain and other tissues. I Drug Target 2002; 10: 327-335
   PubMed Web of Science ®Google Scholar
• Zara GP, Bargoni A, Cavalli R, et al. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002; 91: 1324–1333
   PubMed Web of Science ®Google Scholar